Keymed Biosciences Announces 2025 Annual Results and Business Updates

Contributed by: PR Newswire

Tags

Keymed

More Like This

Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum

Keymed Biosciences Announces Interim Results for First Half of 2024

Keymed Biosciences Announces 2023 Annual Results and Business Updates

Tigermed Announces 2025 Annual Results

Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers

Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors

PR Newswire associated0

Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up

WuXi Biologics Reports Solid 2024 Interim Results